Moderna Therapeutics, a Cambridge company developing a way to enable the in-vivo production of therapeutic proteins, said Wednesday that Joseph Bolen has joined Moderna as its president of research and development.
Previously Bolen was the chief scientific officer and global head of oncology research at Millennium: the Takeda Oncology Company; he served in senior leadership positions at Millennium since 1999.
At Moderna, Bolen will oversee all aspects of R&D, including discovery research, preclinical and clinical development, and clinical operations.
“I am very happy and honored to partner with such an accomplished and thoughtful scientific leader and drug hunter as Joe to build a very special company for patients and our team,’’ Stephane Bancel, president and founding CEO of Moderna, said in a statement.
In a separate statement, Bolen added: ‘‘The global scientific community is just beginning to understand the significant promise of Moderna’s mRNA technology to advance science and improve human health. I am tremendously excited about expanding our knowledge of this new scientific field and pioneering the clinical application of this modality, which holds such great potential to treat a vast array of human diseases.’’
Meanwhile, Millennium Pharmaceutical has been undergoing some changes. In May, Deborah Dunsire resigned suddenly as chief executive after Millennium’s parent, Japan’s Takeda Pharmaceutical Co., folded Millennium’s Cambridge cancer research unit into corporate research and development.
About two weeks ago, it was announced that Dunsire will lead EnVivo Pharmaceuticals Inc. a Watertown company that makes drugs to treat central nervous system disorders.
A July 11 story in The Globe noted that there had been other departures at Millennium as well, Bolen among them.